raclopride
Small moleculeexperimental
Raclopride is a typical antipsychotic. It acts as a selective antagonist on D2 dopamine receptors. It has been used in trials studying Parkinson Disease. — Wikipedia
Clinical trial activity
8 trials · 13 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
2
Earliest trial started Jan 1, 2009 (NCT00832221)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Studied for
- Anhedonia · Phase 4
- Astrocytoma · Phase 1
- Brain Injuries, Traumatic · Phase 1
- Brain Neoplasms · Phase 1
- Cocaine-Related Disorders · Early Phase 1
- Depression · Phase 4
- Feeding and Eating Disorders · Phase 4
- Glioblastoma · Phase 1
- Glioma · Phase 1
- Healthy Volunteers · Early Phase 1
- Obesity · Early Phase 1
- Oligodendroglioma · Phase 1
- Overweight · Early Phase 1
- Psychotic Disorders · Phase 4
Mechanism of action
- Dopamine D2 receptorANTAGONIST
DRD2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC- Mol. weight
- 347.24 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL8809 ↗
- WikipediaRaclopride ↗
- ChEMBLCHEMBL2104769 ↗
Also known as
- 11c raclopride
- raclopride
- raclopride
- raclopride
- raclopride
- raclopride (11c)
- raclopride (11c)
- raclopride c 11
- raclopride c 11
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05282277 | Phase 4 | Apr 20, 2022 | National Institute of Mental Health (NIMH), University of North Carolina at Chapel Hill |
| NCT03648892 | Early Phase 1 (Phase 1) | Sep 21, 2018 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| NCT02169310 | Phase 1 | Nov 18, 2014 | National Institute of Neurological Disorders and Stroke (NINDS), Uniformed Services University of the Health Sciences |
| NCT02233829 | Early Phase 1 (Phase 1) | Sep 3, 2014 | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| NCT02152670 | N/A | May 1, 2014 | Yale University |
| NCT01392209 | Phase 1 | Jul 8, 2011 | Columbia University, Genentech, Memorial Sloan-Kettering Cancer Center, University of California, San Francisco |
| NCT02020408 | Phase 4 | May 1, 2011 | National Institute of Mental Health (NIMH), University of California, San Diego |
| NCT00832221 | Phase 1 | Jan 1, 2009 | AstraZeneca |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Mental Health (NIMH) | Government | 2 | 0 | 1 | 2011 |
| AstraZeneca | For profit | 1 | 1 | 1 | 2009 |
| Columbia University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Genentech | For profit | 1 | 0 | 1 | 2011 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2011 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 1 | 1 | 2018 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 1 | 1 | 2014 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Government | 1 | 1 | 1 | 2014 |
| Uniformed Services University of the Health Sciences | Government | 1 | 0 | 1 | 2014 |
| University of California, San Diego | Academic/Hospital | 1 | 1 | 1 | 2011 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2014 |
13 organizations
Page 1 / 1